Results 231 to 240 of about 84,545 (302)
Hidden No More: Spotlight on Tidal Disruption Events in Active Galactic Nuclei
ABSTRACT Tidal disruption events (TDEs) are typically discovered in previously quiescent galaxies. However, earlier studies have revealed a handful of TDEs occurring in pre‐existing active galactic nuclei (AGN). We discuss AT2019aalc, a promising TDE candidate in an AGN, and compare it to similar sources.
Patrik Milán Veres
wiley +1 more source
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort +8 more
wiley +1 more source
Leadless Pacemaker for Sinus Pauses and Syncope in Pregnancy: A Feasible Alternative to Conventional Pacing. [PDF]
Yokokawa M, Srivasta S, Sheikh AH.
europepmc +1 more source
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
Obstructive Hypertrophic Cardiomyopathy and Interarterial Anomalous Aortic Origin of the Right Coronary Artery (AAORCA) Presenting With Syncope: Multimodal Diagnostic Assessment and Individualized Management. [PDF]
Moyambi J +4 more
europepmc +1 more source
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria +4 more
wiley +1 more source
Syncope in an Athlete With Apical Hypertrophic Cardiomyopathy: Ominous or Orthostatic? [PDF]
Tatapudi S +3 more
europepmc +1 more source
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura +6 more
wiley +1 more source

